NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/08/2023
Back to search
Official data from USPTO
OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
08/12/2023
Trademark type
Combined
Nice classes
5
Filing date
04/01/2022
Registration date
08/08/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/08/2023
Last transaction
08/12/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
03/22/2022
First use in commerce
03/22/2022
Drawing code
3
Owner type
03
Owner location
Princeton, NJ
Examiner
BEAUDRY-TORRES, FAITH
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the term "OPDUALAG" in blue with a curved line over it in light blue and yellow and the term "(NIVOLUMAB AND RELATLIMAB-RMBW)" in blue below it.
Holders and representatives
Holders
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
Representatives
Marilyn F. Kelly BRISTOL-MYERS SQUIBB COMPANY
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/02/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/02/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/02/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/23/2023
PUBO
PUBLISHED FOR OPPOSITION
05/23/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/17/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
04/17/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/17/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/17/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/14/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/13/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/13/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/14/2022
GNRT
NON-FINAL ACTION E-MAILED
10/14/2022
CNRT
NON-FINAL ACTION WRITTEN
10/14/2022
DOCK
ASSIGNED TO EXAMINER
09/30/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/06/2022
NWAP
NEW APPLICATION ENTERED
04/05/2022
Continuous trademark protection
Get notified about every new filing that threatens OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.